2-氧化吲哚-4-甲酸甲酯 | 90924-46-2

• 物质功能分类: 医药中间体 - 吲哚类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 2-氧化吲哚-4-甲酸甲酯
• 中文别名: 4-羧酸甲酯二氢吲哚-2-酮；吲哚-4-甲酸甲酯；2-吲哚酮-4-甲酸甲酯
• 英文名称: methyl 2-oxoindoline-4-carboxylate
• 英文别名: methyl 2-oxo-1,3-dihydroindole-4-carboxylate
• CAS: 90924-46-2
• 化学式: C₁₀H₉NO₃
• mdl: MFCD08277245
• 分子量: 191.186
• InChiKey: FBKDEECWCACPLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933790090

反应信息

• 作为反应物：
  描述：

  2-氧化吲哚-4-甲酸甲酯 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 以61%的产率得到2-吲哚酮-4-羧酸
  参考文献：
  名称：

  [EN] AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES
  [FR] IMMUNOMODULATEURS À BASE D'AMINOCYLINDAZOLE POUR LE TRAITEMENT DE MALADIES AUTO-IMMUNES

  摘要：

  公开了式I或式II的2-酰基吲唑化合物。这些化合物抑制凝血因子XIIa。它们可用于治疗自身免疫疾病。

  公开号：

  WO2017205296A1
• 作为产物：
  描述：

  2-甲基-3-硝基苯甲酸 在 盐酸 、 N-溴代丁二酰亚胺(NBS) 、 氯化亚砜 、 palladium 10% on activated carbon 、 氢气 、 过氧化苯甲酰 作用下， 以 甲醇 、 四氯化碳 、 水 为溶剂， 反应 19.0h， 生成 2-氧化吲哚-4-甲酸甲酯
  参考文献：
  名称：

  Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation

  摘要：

  A series of AG014699 derivatives containing a novel scaffold of 2,3-dihydro-1H-[1,2] diazepino[4,5,6-cd] indole-1,4(6H)-dione were synthesized and evaluated for their inhibitory activities toward PARP-1 enzyme and two cell lines, MCF-7 cells and the BRCA1-deficient MDA-MB-436 cells. Our results demonstrated that of all AG014699 derivatives synthesized in this work, compounds 6 and 7 showed strong PARP-1 inhibitory activity (IC50 = 3.5 nM and 2.4 nM, respectively), only four and three times less potent than AG014699. Compound 6 also had significantly cell inhibitory activity against both MCF-7 cells (CC50 = 25.8 mu M) and the BRCA1-deficient MDA-MB-436 cells (CC50 = 5.4 mu M), nearly as good as AG014699, indicating that it can be a promising compound for further evaluation. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.08.060

文献信息

• [EN] SUBSTITUTED INDOLE MCL-1 INHIBITORS<br/>[FR] INHIBITEURS D'INDOLES MCL-1 SUBSTITUÉS
  申请人：UNIV VANDERBILT

  公开号：WO2017152076A1

  公开（公告）日：2017-09-08

  The present disclosure provides for compounds that inhibit the activity of an anti- apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present disclosure also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over- expression or dysregulation of Mcl-1 protein.

  本公开提供了抑制抗凋亡Bcl-2家族成员髓细胞白血病-1（Mcl-1）蛋白活性的化合物。本公开还提供了用于治疗由Mcl-1蛋白过度表达或失调所特征的疾病和病况（例如癌症）的药物组合物以及使用化合物的方法。
• Methods of modulating tyrosine protein kinase function with indolinone compounds
  申请人：SUGEN, INC.

  公开号：US20030203901A1

  公开（公告）日：2003-10-30

  The invention relates to certain indolinone compounds, their method of synthesis, and a combinatorial library consisting of the indolinone compounds. The invention also relates to methods of modulating the function of protein tyrosine kinases using indolinone compounds and methods of treating diseases by modulating the function of protein tyrosine kinases and related signal transduction pathways.

  该发明涉及某些吲哚酮化合物，它们的合成方法以及由吲哚酮化合物组成的组合式库。该发明还涉及使用吲哚酮化合物调节蛋白酪氨酸激酶功能的方法，以及通过调节蛋白酪氨酸激酶和相关信号转导途径的功能来治疗疾病的方法。
• Indolinone combinatorial libraries and related products and methods for the treatment of disease
  申请人：Tang Cho Peng

  公开号：US20050197382A1

  公开（公告）日：2005-09-08

  The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting protein kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis and restenosis and metabolic diseases such as diabetes. The present invention features indolinone compounds that potently inhibit protein kinases and related products and methods. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone, in particular at the 1′ position of the indole ring. Indolinone compounds that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano-b-pyrrol moiety. Indolinone compounds that are modified with substituents, particularly at the 5 position of the oxindole ring, can effectively activate protein kinases. This invention also features novel hydrosoluble indolinone compounds that are tyrosine kinase inhibitors and related products and methods.

  本发明涉及有机分子，能够调节、调控和/或抑制蛋白激酶信号转导。这些化合物对于治疗与不受调节的蛋白激酶信号转导相关的疾病非常有用，包括细胞增殖性疾病，如癌症、动脉粥样硬化、关节炎、再狭窄和代谢性疾病，如糖尿病。本发明涉及具有强效抑制蛋白激酶和相关产品以及方法的吲哚酮化合物。特定于FLK蛋白激酶的抑制剂可以通过在吲哚环的1'位置添加化学取代基来获得3-[(吲哚-3-基)亚甲基]-2-吲哚酮。特异性抑制FLK和血小板衍生生长因子蛋白激酶的吲哚酮化合物可以具有四氢吲哚或环戊烯基-β-吡咯基。在氧吲哚环的5位取代基的修饰下，吲哚酮化合物可以有效激活蛋白激酶。本发明还涉及新型水溶性吲哚酮化合物，它们是酪氨酸激酶抑制剂和相关产品和方法。
• Biphenyl-substituted quinoline derivatives
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US06117885A1

  公开（公告）日：2000-09-12

  Compounds of the formula ##STR1## wherein X, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, A, B, D and E are as defined herein. These compounds inhibit the action of angiotensin II and are useful, therefore, for example, as antihypertensive agents.

  公式为##STR1##的化合物，其中X，R.sub.1，R.sub.2，R.sub.3，R.sub.4，R.sub.5，R.sub.6，A，B，D和E的定义如本文所述。这些化合物抑制血管紧张素II的作用，因此例如作为降压剂等方面是有用的。
• Discovery of Potent, Selective Chymase Inhibitors via Fragment Linking Strategies
  作者：Steven J. Taylor、Anil K. Padyana、Asitha Abeywardane、Shuang Liang、Ming-Hong Hao、Stéphane De Lombaert、John Proudfoot、Bennett S. Farmer、Xiang Li、Brandon Collins、Leslie Martin、Daniel R. Albaugh、Melissa Hill-Drzewi、Steven S. Pullen、Hidenori Takahashi

  DOI：10.1021/jm400138z

  日期：2013.6.13

  Chymase plays an important and diverse role in the homeostasis of a number of cardiovascular processes. Herein, we describe the identification of potent, selective chymase inhibitors, developed using fragment-based, structure-guided linking and optimization techniques. High-concentration biophysical screening methods followed by high-throughput crystallography identified an oxindole fragment bound to the S1 pocket of the protein exhibiting a novel interaction pattern hitherto not observed in chymase inhibitors. X-ray crystallographic structures were used to guide the elaboration/linking of the fragment, ultimately leading to a potent inhibitor that was >100-fold selective over cathepsin G and that mitigated a number of liabilities associated with poor physicochemical properties of the series it was derived from.